A detailed history of Capital Advisors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital Advisors Inc holds 12,760 shares of BMY stock, worth $506,061. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,760
Previous 12,738 0.17%
Holding current value
$506,061
Previous $653,000 5.82%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$47.98 - $54.4 $1,055 - $1,196
22 Added 0.17%
12,760 $691,000
Q4 2023

Jan 29, 2024

SELL
$48.48 - $57.85 $7,029 - $8,388
-145 Reduced 1.13%
12,738 $653,000
Q3 2023

Oct 24, 2023

SELL
$57.89 - $64.73 $113,811 - $127,259
-1,966 Reduced 13.24%
12,883 $747,000
Q2 2023

Jul 18, 2023

BUY
$63.71 - $70.74 $53,261 - $59,138
836 Added 5.97%
14,849 $949,000
Q1 2023

Apr 19, 2023

SELL
$65.71 - $74.53 $27,203 - $30,855
-414 Reduced 2.87%
14,013 $971,000
Q4 2022

Jan 17, 2023

SELL
$68.48 - $81.09 $57,797 - $68,439
-844 Reduced 5.53%
14,427 $0
Q3 2022

Oct 17, 2022

BUY
$0.13 - $76.84 $193 - $114,107
1,485 Added 10.77%
15,271 $1.09 Million
Q2 2022

Jul 15, 2022

SELL
$72.62 - $79.98 $8,278 - $9,117
-114 Reduced 0.82%
13,786 $1.06 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $74,636 - $89,496
-1,214 Reduced 8.03%
13,900 $1.02 Million
Q4 2021

Jan 27, 2022

SELL
$53.63 - $62.52 $15.9 Million - $18.5 Million
-295,657 Reduced 95.14%
15,114 $942,000
Q3 2021

Oct 25, 2021

BUY
$59.17 - $69.31 $194,136 - $227,406
3,281 Added 1.07%
310,771 $18.4 Million
Q2 2021

Aug 02, 2021

BUY
$61.91 - $67.42 $1.53 Million - $1.66 Million
24,634 Added 8.71%
307,490 $20.5 Million
Q1 2021

May 25, 2021

BUY
$59.34 - $66.74 $1.22 Million - $1.37 Million
20,526 Added 7.82%
282,856 $17.9 Million
Q4 2020

Feb 08, 2021

BUY
$57.74 - $65.43 $1.95 Million - $2.21 Million
33,721 Added 14.75%
262,330 $16.3 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $649,648 - $719,895
11,312 Added 5.21%
228,609 $13.8 Million
Q2 2020

Aug 07, 2020

BUY
$54.82 - $64.09 $10.8 Million - $12.6 Million
196,686 Added 954.28%
217,297 $13.3 Million
Q1 2020

May 21, 2020

SELL
$46.4 - $67.43 $41,992 - $61,024
-905 Reduced 4.21%
20,611 $1.15 Million
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $62,299 - $81,264
1,266 Added 6.25%
21,516 $1.38 Million
Q2 2019

Aug 07, 2019

BUY
$44.62 - $49.34 $481,583 - $532,526
10,793 Added 114.13%
20,250 $0
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $561,879 - $669,971
-12,453 Reduced 56.84%
9,457 $0
Q4 2018

Feb 06, 2019

BUY
$48.76 - $63.23 $35,984 - $46,663
738 Added 3.49%
21,910 $1.14 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $3,642 - $4,108
-66 Reduced 0.31%
21,172 $1.31 Million
Q2 2018

Aug 06, 2018

SELL
$50.53 - $62.98 $7.12 Million - $8.87 Million
-140,838 Reduced 86.9%
21,238 $0
Q1 2018

May 04, 2018

BUY
$59.92 - $68.98 $387,442 - $446,024
6,466 Added 4.16%
162,076 $0
Q4 2017

Jan 29, 2018

SELL
$59.94 - $65.35 $70,729 - $77,113
-1,180 Reduced 0.75%
155,610 $9.54 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $225,283 - $259,995
-4,079 Reduced 2.54%
156,790 $9.99 Million
Q2 2017

Aug 09, 2017

BUY
N/A
160,869
160,869 $8.96 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital Advisors Inc Portfolio

Follow Capital Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Capital Advisors Inc with notifications on news.